Price
No data yet.
Social Signal Score
Analyst Ratings
26 analystsRevenue
$11.89M+1135.97%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Gilmore O'Neill
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 87
- Beta
- 2.09
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -8.09
Financials
Revenue
$11.89M+1136.0%Net Income
$-18.23MEBITDA
$-19.52MFree Cash Flow
$-29.67MEPS (diluted)
$-0.15Shares Outstanding (diluted)
119.29M+236.0%Operating Expenses
$31.78MCash & Debt
$211.65MReturn of Capital
$0.00Revenue by Segment (annual)
$40.52MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $40.52M | $-160.06M | $-1.80 |
| 2024 | $32.31M | $-237.09M | $-2.88 |
| 2023 | $78.12M | $-153.22M | $-2.02 |
| 2022 | $19.71M | $-220.43M | $-3.21 |
| 2021 | $25.54M | $-192.50M | $-2.85 |
| 2020 | $90.73M | $-115.98M | $-1.98 |
| 2019 | $20.53M | $-133.75M | $-2.47 |
| 2018 | $31.94M | $-109.95M | $-2.33 |
| 2017 | $13.73M | $-120.32M | $-2.98 |
| 2016 | $6.05M | $-97.18M | $-3.02 |
| 2015 | $1.63M | $-72.90M | $-2.04 |
| 2014 | $0.00 | $-13.69M | $-5.34 |
| 2013 | $0.00 | $-5.35M | $-0.18 |
Valuation
EDIThas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
150+172.73%Social Signal Score
Mentions (5)
- Newsglobenewswire.com·27d ago·Neutral
Editas Medicine Reports Inducement Grants to New Chief Medical Officer CAMBRIDGE, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, today announced the grant of an inducement award to the Company's newly appointed Chief Medical Officer, Daniel Ory, M.D.
View source ↗ - Newsmarketbeat.com·27d ago·Neutral
Editas Medicine Eyes First Human Trial for CRISPR Cholesterol Therapy EDIT-401 Editas Medicine NASDAQ: EDIT is preparing to begin a first-in-human study of EDIT-401, an in vivo CRISPR-edited medicine designed to lower LDL cholesterol in patients with heterozygous familial hypercholesterolemia, Chief Executive Officer Gilmore O'Neill said during a Wells Fargo discussion.
View source ↗ - Newsglobenewswire.com·28d ago·Neutral
Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer Experienced biotechnology executive with more than 25 years of leadership in cardiovascular and genetic medicine to lead clinical development
View source ↗ - Newsglobenewswire.com·35d ago·Neutral
Editas Medicine to Participate in Upcoming Investor Conferences CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that management will participate in the following upcoming investor conferences in September: Wells Fargo Healthcare Conference Format: Fireside ChatDate: Tuesday, September 8Time: 4:30 p.m.
View source ↗ - Newszacks.com·56d ago·Neutral
Is Editas Medicine (EDIT) Outperforming Other Medical Stocks This Year? Here is how Editas Medicine (EDIT) and Amylyx Pharmaceuticals, Inc. (AMLX) have performed compared to their sector so far this year.
View source ↗
Earnings
Mon, Nov 9(in 5 weeks)
Consensus estimate $-0.21 per share
Typical surprise +13.3% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 5$-0.15 vs $-0.27beat
- Tue, May 5$-0.26 vs $-0.30beat
- Mon, Mar 9$-0.06 vs $-0.27beat
- Mon, Nov 10$-0.28 vs $-0.38beat
- Tue, Aug 12$-0.63 vs $-0.41miss
- Mon, May 12$-0.92 vs $-0.56miss
Estimates and results for EDIT via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by EDIT officers and directors.
- Bought
- $254k
- Sold
- $1.6m
1 trade
45 trades
- Burkly Lindasold
- Parison Amysold
- O'neill Gilmore Neilsold
- Parison Amysold
- Burkly Lindasold
- Parison Amysold
- O'neill Gilmore Neilsold
- Burkly Lindasold
54 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Daniel Goldmanhouse · NY10 · disclosed May 19, 2023 (39d later)Sell$1,001 - $15,000
- Donald Sternoff Beyerhouse · VA08 · disclosed May 1, 2021 (17d later)Sell$1,001 - $15,000
- Donald Sternoff Beyerhouse · VA08 · disclosed Apr 1, 2021 (30d later)Sell$1,001 - $15,000
- Donald Sternoff Beyerhouse · VA08 · disclosed Dec 1, 2020 (14d later)Buy$1,001 - $15,000
- Donald Sternoff Beyerhouse · VA08 · disclosed May 31, 2020 (30d later)Sell$1,001 - $15,000
- Donald Sternoff Beyerhouse · VA08 · disclosed May 9, 2020 (12d later)Sell$1,001 - $15,000
- Donna Shalalahouse · FL27 · disclosed Apr 27, 2020 (328d later)Sell$1,001 - $15,000
- Donna Shalalahouse · FL27 · disclosed Apr 27, 2020 (418d later)Buy$1,001 - $15,000
- Donald Sternoff Beyerhouse · VA08 · disclosed Feb 22, 2020 (44d later)Buy$1,001 - $15,000
- Donald Sternoff Beyerhouse · VA08 · disclosed Feb 22, 2020 (26d later)Buy$1,001 - $15,000
- Donald Sternoff Beyerhouse · VA08 · disclosed Jan 2, 2020 (10d later)Buy$1,001 - $15,000
- James Mountain Inhofesenate · OK · disclosed Dec 20, 2019 (319d later)Sell$15,001 - $50,000
- James Mountain Inhofesenate · OK · disclosed Feb 25, 2019 (21d later)Sell$15,001 - $50,000
- James Mountain Inhofesenate · OK · disclosed Nov 8, 2017 (20d later)Buy$15,001 - $50,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.